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complication in Balloon-expendable (BE) and Self-expendable (SE) TAVI procedures
remain unclear.
Methods: 2,769 patients consecutive with a successful procedure and a predischarge
transthoracic echocardiography (TTE) were enrolled in 33 centers. Mean follow-up was
302164 days.
Results: Mean age was 837 years; 49% were female and logistic EuroSCORE was
21.513.8. BE and SE devices was implanted in 67.6% (n1872) and 32.4% (n897),
respectively. Approaches were femoral (75.4%) or non femoral: subclavian (5.6%),
transapical (17.2%) or transaortic (1.8%). A perivalvular AR2 was observed in 14.9%.
Its occurrence was 2 fold higher in SE (19.8%) than in BE-TAVI procedures (12.2%,
p0.0001). This remained significant in multivariate analysis (adjusted HR2.01,
p0.0001). A perivalvular AR2 was associated with a mortality at 1 year (24.2%) twice
higher than in patients without AR (11.9%) (p0.0001). This figure was similar for BE
(27.1% vs 12.0%) and SE-TAVI (20.5% vs 11.8%) procedures. By multivariate analysis,
a perivalvular AR2 was the strongest predictor of 1 year mortality (ad. HR2.35
[1.75-3.15]; p0.0001). This figure was similar for BE (ad. HR2.68) and SE-TAVI (ad.
HR2.10) procedures. For BE-TAVI procedures, male gender (ad. HR1.66, p0.001),
a device diameter/aortic annulus diameter Ratio 1.1 (ad. HR1.83, p0.0001) and a
femoral approach (ad. HR1.70, p0.006) were the 3 major independent predictors of
AR2. For SE-TAVI procedures, male gender (ad. HR1.61, p0.01) and a femoral
approach (ad.HR2.1, p0.008) were 2 independent predictors of AR2. Importantly,
device diameter/aortic annulus diameter Ratio was not a predictor of AR for SE-TAVI
procedures.
Conclusions: Post-procedural perivalvular AR2 was observed in 15% of successful
TAVI procedures. Its occurrence doubled the 1-year mortality rate and was the strongest
and independent predictor of 1-year mortality for both BE and SE-TAVI procedures.
Analysis of predictors of AR suggests that device-type and procedural characteristics may
impact the occurrence of AR.
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Background: The presence of mitral regurgitation (MR) is an independent predictor of
mortality after conventional aortic valve replacement for aortic stenosis. The predictive
value of pre-procedural MR on clinical outcome after TAVI is unknown.
Methods: 3,195 consecutive patients were enrolled in 33 centres. MR was graded
according to pre-procedural transthoracic echocardiography (TTE) as none/trivial(0),
mild(1), moderate(2), moderate-to-severe(3), or severe(4). The mean age was
827 years; 49% were female and mean logistic EuroSCORE was 21.914.3. Balloon
(BE) and self-expendable (SE) devices were implanted in 66.9% and 33.1% of patients,
respectively. Approaches were transarterial (transfemoral: 74.6%; subclavian: 5.8%),
transapical (17.8%), and transaortic (1.8%).
Results: Pre-procedural TTE showed no MR in 32% of cases, a grade 1 MR in 46% of
cases, a grade 2 MR in 20% of cases and a grade 3-4 in 2% of cases. Procedural success
rate was 96.9%. Actuarial 1 year mortality was 19.5%. By univariate analysis, pre-
procedural MR grade2, MR Grade1 and MR Grade0 were associated with a 1 year
mortality of 24.0%, 20.1% and 15.8%, respectively (p0.002). By multivariate analysis,
4 independent baseline characteristics were associated with preprocedural MR: a higer
Logistic EuroSCORE (p0.0001), a lower ejection fraction (p0.0002), a higher NYHA
class (p0.0007), and female gender (p0.001). By multivariate Cox analysis, indepen-
dent predictors of one-year mortality were: logistic EuroSCORE (p0.0001), NYHA
class (p0.0001) and transapical approach (p0.0005). The presence of preprocedural
MR was not significantly associated with 1-year mortality (p0.31). Results did not differ
when analyses were restricted only to BE or only to SE devices.
Conclusions: A mild(grade1) or a moderate(grade 2) MR preprocedural is associated
with a higher 1-year mortality after TAVI. However, since preprocedural MR is
associated with a higher NYHA class or a higher logistic Euroscore, pre-procedural MR
is not an independent predictor of mortality. These findings suggest that, in itself, the
presence of a mild or a moderate MR should not refrain from performing TAVI and
should not impact the type of valve to be used.
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Background: The Placement of Aortic Transcatheter Valves (PARTNER) trial Cohort A
demonstrated similar survival after transcatheter and surgical aortic valve replacement
(TAVR and SAVR, respectively) in high-risk operable patients with symptomatic, severe
aortic stenosis (AS). The impact of valve replacement technique on left ventricular (LV)
function and the effects of LV dysfunction on clinical outcomes are unknown.
Methods: The PARTNER trial randomized high-risk patients with severe AS to TAVR
or SAVR. Echocardiographic evaluation was performed at baseline, hospital discharge,
1-, 6-, and 12-months. Patients were stratified by the presence of LV dysfunction
(LVEF50%).
Results: In patients with LV dysfunction (N215), mean LV ejection fraction (LVEF)
increased from 369 to 4912% 1-year after TAVR and from 389 to 4912% after
SAVR (pNS). At 1-year, LVEF was unchanged in patients with preserved LV function
(N454) in both treatment groups. All-cause mortality was similar for TAVR and SAVR
at 30-days and 1-year regardless of baseline LV function and valve replacement technique
(Figure). Rates of repeat hospitalization at 1-year follow-up were comparable with TAVR
and SAVR in patients with reduced (25.6 vs17.1%, pNS) and preserved (11.7 vs 14.8%,
pNS) LV function, as were functional class and 6-minute walk test.
Conclusions: In high-risk patients with severe AS and LV dysfunction, improvements in
LVEF were similar after TAVR and SAVR. Mortality rates were comparable between
valve replacement techniques regardless of LV function.
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Background: The outcomes of severe aortic stenosis (AS) patients with chronic
obstructive pulmonary disease (COPD) undergoing transcatheter aortic valve replacement
(TAVR) have not been systematically studied. The present study aimed to evaluate the
impact of COPD on the outcome of patients treated for severe AS across all treatment
modalities.
Methods: All patients included in the PARTNER trial and who underwent TAVR,
including continued access patients, (n1938) were evaluated for outcome according to
COPD severity, stratified into no COPD, non-oxygen-dependent (non-O2 dep) COPD and
oxygen-dependent (O2 dep) COPD. Outcomes of COPD patients in the different study
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